Report Scope: This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3 and CD47/SIRP?. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins and Chimeric Antigen Receptor (CAR) T cells.
Report Includes: - 21 data tables and 43 additional tables - An overview of the global market for checkpoint inhibitors - Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023 - Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs - Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape - Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRP? agents - Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro, Inc. and Xencor
Summary The treatment of cancer patients involves a multidisciplinary approach encompassing surgery, radiotherapy, and chemotherapy.Traditionally, patients with metastatic disease are treated with combination cytotoxic chemotherapy or targeted agents; although chemotherapy treatment has good response rates complete responses are rarely seen.
During the last decade the field of immuno-oncology has rapidly advanced and a number of agents which modulate the immune system are beginning to emerge and change treatment paradigms. Two of the most prominent and promising class of drugs are the immune checkpoint inhibitors, that target the proteins found on T-lymphocytes or T cells such as programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathways.
The immune checkpoint inhibitors are causing a stir amongst oncologist as they have been shown to be effective in the treatment of a variety of cancers, enhancing the immune response to detect and target cancer cells with a lower incidence of side effects compared to conventional chemotherapy and providing durable responses, lasting for many years. Five checkpoint inhibitors have received rapid approval from the U.S. Food and Drug Administration for cancer, including the PD-1 inhibitors Keytruda (pembrolizumab), and Opdivo (nivolumab), the PD-L1 inhibitors Tecentriq (atezoliumab), Bavencio (avelumab) and Imfinzi (durvalumab) and the CTLA-4 inhibitor Yervoy (ipilimumab). In 2011, Bristol Myers Squibb’s Yervoy a CTLA-4 inhibitor became one of the first checkpoint inhibitor to be approved in the treatment of metastatic melanoma, despite considerable safety and tolerability concerns. It took a further 3 years before the next checkpoint inhibitor Keytruda, a PD-1 inhibitor was approved for the treatment of advanced unresectable melanoma.
Since 2013, over REDACTED has been invested by pharma companies in acquisitions, equity offerings and venture capital and a further REDACTED has been transacted in the establishment of strategic partnerships associated with the development of checkpoint inhibitors. According to clincailtrial.org there are more than 230 clinical trials underway evaluating checkpoint inhibitors either as a monotherapy or in combination with chemotherapy or targeted therapies these encompass a wide variety of caner sub-types: including 117 Phase 1 trials, 112 Phase 2 trial and 9 Phase 3 studies. Several novel agents are in early stage clinical development that target novel pathways including the T cell immunoglobulin and mucin containing protein 3 (TIM-3) and lymphocyte-activation gene 3 (LAG-3) protein inhibitors, CD-47/signal regulatory protein ? (SIRP?) and immunometabolic enzymes Indoleamine 2,3-dioxygenase-1 (IDO-1) which utilize an array of innovative delivery technologies such as small molecule agents, monoclonal antibodies, bispecific antibodies and fusion proteins to target inhibit checkpoint proteins.
In 2017, checkpoint inhibitors generated sales of nearly REDACTED and by 2023 we forecast these agents will garner over REDACTED in revenues as marketed therapies gain regulatory approval in new indications and territories.In addition, novel classes if checkpoint inhibitors will enter the market, companies will identify clinically effective combinations and validate biomarkers and signatures that will enable them to help identify patients that are most likely to benefit from treatment.
Personalized precision medicine will be a major driver for pharma to effectively deliver these innovative medicines and ensure they are accessible and available at sustainable prices to all those in need.
Our reports have been used by over 10K customers, including:
199 pages •
By Asia Market Information & Development Company
• May 2021
China’s demand for Colon Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
283 pages •
By Global Industry Analysts
• Apr 2021
- Global Gynaecological Cancer Drugs Market to Reach $36.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Gynaecological Cancer Drugs estimated at US$26.7 Billion in the year 2020, is projected to reach a revised size of US$36.9 Billion by 2027, growing at a CAGR of 4.8% over the analysis...
48 pages •
By Asia Market Information & Development Company
• May 2021
This study focuses on China’s Colon Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy....
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
120 pages •
By Infiniti Research Limited
• Jun 2021
Global Bone Cancer Drugs Market 2021-2025 The analyst has been monitoring the bone cancer drugs market and it is poised to grow by USD 996.69 mn during 2021-2025, progressing at a CAGR of 5.46% during the forecast period. Our report on the bone cancer drugs market provides a holistic analysis, market size and forecast,...
TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 18.104.22.168) - Drugs in Development, 2021 Summary According to the recently published report ’TGF Beta Receptor Type 2 - Drugs in Development, 2021’; TGF Beta Receptor Type 2 (Transforming Growth Factor Beta...
Heparanase - Drugs In Development, 2021 Summary Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 22.214.171.124) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report...
Myc Proto Oncogene Protein - Drugs In Development, 2021 Summary Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining...
Global Radiation Therapy in the Oncology Market to Reach $9,206.6 Million by 2031 Market Report Coverage - Radiation Therapy in the Oncology Market Segmentation • Radiation – External Beam Radiation, Internal Beam Radiation • Product – Oncology Systems, Particle Therapy Systems (Proton...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.